Reports

The burden of acute coronary syndrome: The second leading cause of death in Canada

November 1, 2010

CRA was commissioned by AstraZeneca to investigate the economic and societal burden associated with Acute Coronary Syndrome (ACS) in Canada. This short paper represents a summary of the full report.

Download

Related capabilities

Life Sciences

Tim Wilsdon
Vice President

London
+44 20-7664-3707 twilsdon@crai.com

Intellectual Property
Articles

Anticompetitive conduct and patents listed in the Orange Book

Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...
Life Sciences
Infographics

NCDs & long-term antimicrobial therapy

1 in 4 people globally are already affected by NCDs. By 2030, NCDs will cause 55 million deaths per year under ‘business as usual.’1,2 Effective...

Explore our thinking

Life Sciences
Speaking Engagement

December 9, 2025

Virtual

Sex and Gender in the Patient Journey: Lessons from Alzheimer’s Disease Webinar

Tunahan Kirabali is a speaker during the webinar about sex and gender differences in the Alzheimer’s patient journey highlighting implications for clinical...

See all events

The burden of acute coronary syndrome: The second leading cause of death in Canada

Key contacts

Related insights

Anticompetitive conduct and patents listed in the Orange Book

NCDs & long-term antimicrobial therapy

Upcoming events

Sex and Gender in the Patient Journey: Lessons from Alzheimer’s Disease Webinar